| 李丽,郭孟刚,罗晓斌,等.基于 SEER数据库分析肺腺癌的发病率及生存趋势[J].安徽医药,2023,27(9):1796-1799. |
| 基于 SEER数据库分析肺腺癌的发病率及生存趋势 |
| Trends in the incidence and survival of lung adenocarcinoma: an analysis and research based on SEER database |
| |
| DOI：10.3969/j.issn.1009-6469.2023.09.022 |
| 中文关键词: 腺癌，细支气管肺泡 年龄因素 发病率 生存率 SEER数据库 |
| 英文关键词: Adenocarcinoma,bronchiolo-alveolar Age factors Incidence Survival SEER database |
| 基金项目:四川省卫生健康委科技项目( 18PJ409) |
|
| 摘要点击次数: 403 |
| 全文下载次数: 400 |
| 中文摘要: |
| 目的研究肺腺癌流行病学的最新趋势。方法利用监测、流行病学和最终结果数据库( SEER)收集 2000年 1月至 2016年 12月肺腺癌病人资料，分析年龄调整后的发病率、年龄标准化后的相对生存率变化趋势。结果共纳入肺腺癌病人 310 702例，年龄调整后发病率分别从 2000年的 21.3/100 000上升到 2016年的 21.5/100 000，特别是在女性、年龄 ≥70岁、黑种人、美洲印第安人 /阿拉斯加原住民( AI/AN)、亚洲 /太平洋岛民( API)、病理分级 Ⅰ级、局限期和远处转移者中，分别从 2000年的18.6/100000、110.3/100 000、22.4/100 000、6.5/100 000、16.6/100 000、1.7/100 000、4.3/100 000、11.0/100 000上升至 2016年的20.8/100000、135.0/100 000、23.8/100 000、8.5/100 000、19.1/100 000、2.0/100 000、5.5/100 000、11.4/100 000，其中年龄 ≥70岁者升高幅度最大，但在男性、 <60岁、 60~<70岁、白种人、病理分级为 Ⅱ~Ⅳ级以及局部转移者中，经年龄调整后的发病率是降低的，分别从 2000年的 25.0/100 000、5.8/100 000、85.4/100 000、21.6/100 000、4.3/100 000、6.5/100 000、0.2/100 000、4.8/100 000降至 2016年的 22.5/100 000、4.7/100 000、69.8/100 000、21.4/100 000、4.0/100 000、4.4/100 000、0.1/100 000、4.2/100 000，其中 60~< 70岁者降低幅度最大。研究期间，经年龄标准化后的 3年相对生存率和 5年相对生存率均是升高的，分别从 2000年的 26.2%、20.3%上升到2016年的 32.7%、25.0%。亚组分析发现，女性、 60~<70岁、 API、病理分级 Ⅰ级、局部转移者的 3年、 5年相对生存率升高得较明显，其 3年相对生存率分别从 2000年的 30.8%、27.5%、27.6%、53.0%、41.0%上升至 2011年的 37.7%、35.9%、39.3%、67.6%、52.6%，其 5年相对生存率分别从 2000年的 24.1%、21.1%、18.8%、46.3%、29.9%上升至 29.3%、27.2%、27.7%、61.1%、41.5%。结论总体上，肺腺癌经年龄调整后的发病率略有升高，经年龄标准化后的相对生存率逐渐升高。其中，病理分级较低、局限期发病率和生存率的升高可能得益于肺癌筛查及治疗水平的提高。 |
| 英文摘要: |
| Objective To investigate the latest trends of epidemiology of lung adenocarcinoma (LADC).Methods The data of pa-tients with LADC from January 2000 to December 2016 were obtained from the Surveillance, Epidemiological, and End Results (SEER)database, and the trends of age-adjusted incidence and age-standardized relative survival rate were analyzed.Results A total of 310 702 cases of LADC were included. The age-adjusted incidence of LADC increased slightly from 21.3/100 000 in 2000 to 21.5/100 000 in2016, especially among populations of females, older than age 70 years, blacks, American Indian/Alaska Native (AI/AN), Asian/PacificIslander (API), and those with pathological grading Ⅰ, limited stage, and distant metastasis, the incidences increased from 18.6/100 000,110.3/100 000, 22.4/100 000, 6.5/100 000, 16.6/100 000, 1.7/100 000, 4.3/100 000 and 11.0/100 000 in 2000 to 20.8/100 000, 135.0/100 000, 23.8/100 000, 8.5/100 000, 19.1/100 000, 2.0/100 000, 5.5/100 000 and 11.4/100 000 in 2016 respectively. The incidenceincreased the largest among population aged 70 years or above. The age-adjusted incidences of LADC decreased among populations ofmen, younger than 60 years old, aged from 60 to younger than 70 years old, whites, and those with pathological grading Ⅱ-Ⅳ and local metastasis from 25.0/100 000, 5.8/100 000, 85.4/100 000, 21.6/100 000, 4.3/100 000, 6.5/100 000, 0.2/100 000 and 4.8/100 000 in2000 to 22.5/100 000, 4.7/100 000, 69.8/100 000, 21.4/100 000, 4.0/100 000, 4.4/100 000, 0.1/100 000 and 4.2/100 000 in 2016 re-spectively. The incidence decreased the largest in population aged from 60 to younger than 70 years old. The age-standardized 3-year and 5-year relative survival rates increased during the study period from 26.2% and 20.3% in 2000 to 32.7% and 25.0% in 2016 re-spectively. Subgroup analysis results showed that the 3-year and 5-year relative survival rates in populations of female, aged from 60 to younger than 70 years old, API, and those with pathological grading I and local metastasis increased significantly. The 3-year relativesurvival rates increased from 30.8%, 27.5%, 27.6%, 53.0% and 41.0% in 2000 to 37.7%, 35.9%, 39.3%, 67.6% and 52.6% in 2011 re-spectively, meanwhile the 5-year relative survival rate increased from 24.1%, 21.1%, 18.8%, 46.3% and 29.9% in 2000 to 29.3%,27.2%, 27.7%, 61.1% and 41.5% in 2011 respectively.Conclusions Overall, the age-adjusted incidence of lung adenocarcinoma in- creased slightly, and the age-standardized relative survival rates of lung adenocarcinoma gradually increased. Among them, the in-crease in the incidence and survival rate of patients with lower pathological grading and limited stage may benefit from lung cancerscreening and the improvement of treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
